Janssen applies to FDA for New Indication of XARELTO® for Peripheral Artery Disease
The Janssen Pharmaceutical Companies of Johnson & Johnson revealed on Monday the submission of the supplemental New Drug Application (sNDA)
Read more
Regulatory
AstraZeneca receives FDA authorisation to resume COVID-19 vaccine trial
AstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read more
FDA approves Roche’s Venclexta combos for acute myeloid leukaemia
Roche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read more
SYNLAB validates saliva sampling method for SARS-CoV-2 testing
SYNLAB, leading European provider of medical diagnostic solutions, has revealed the successful authorization of saliva sampling platform, another groundbreaking non-invasive
Read more
AstraZeneca’s FARXIGA® gets designation for Chronic Kidney Disease
AstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read more
Janssen’s Golimumab gets FDA nod for pediatric use in Juvenile Arthritis
Janssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read more
Algernon gets FDA nod for human study of Ifenprodil for COVID-19
Algernon has received the FDA’s approval for the commencement of a Phase 2 and 3 human study of it’s repurposed
Read more
Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
FDA clears Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for GIST
Deciphera Pharmaceuticals, Inc. has revealed that QINLOCK™ (ripretinib) was formally authorised by the U.S. Food and Drug Administration (FDA) for
Read more
FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read more